iBio, Inc. (IBIO) Stock: Here’s Why It’s Down


iBio, Inc. (IBIO) is working its way for to the bottom in the market today. The company, focused in the biotechnology space, is currently priced at $0.21 after heading down -43.26% so far today. As it relates to biotechnology companies, there are several factors that have the ability to lead to movement in the market. News is one of the most common reasons for movement. Here are the most recent headlines centered around IBIO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-25-19 08:30AM iBio, Inc. Prices $5,000,000 Public Offering
Oct-22-19 04:30PM iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan
Sep-19-19 01:58PM One Thing To Remember About The iBio, Inc. (NYSEMKT:IBIO) Share Price
Sep-17-19 04:15PM iBios Collaboration with South Africas AzarGen Biotechnologies Advances to Next Stage
Aug-26-19 05:30PM iBio and CC-Pharming Expand Business Collaboration in China

However, when making an investing decision, prospective investors should look at far more than news, this is especially the case in the generally speculative biotechnology sector. Here’s what’s happening with iBio, Inc..

What We’ve Seen From IBIO

Although a single session decline, like the fall that we’re seeing from iBio, Inc. may lead to fear in some investors, that by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It’s always a good idea to dig into trends for a period longer than a single session. As it relates to IBIO, below are the returns on investment that investors have experienced:

  • Past Seven Days – Over the past week, IBIO has generated a change in value that amounts to -59.65%.
  • Monthly – The ROI from iBio, Inc. in the past 30 days works out to -62.50%.
  • Past Three Months – Throughout the last three months, the company has produced a return that works out to -69.57%
  • Bi-Annually – Throughout the last six months, we have seen a performance that works out to -74.55% from the company.
  • Year To Date – Since the open of this year IBIO has produced a ROI of -72.13%.
  • Annually – Lastly, in the past full year, investors have seen movement of -72.51% out of IBIO. In this period, the stock has traded at a high price of -85.00% and a low price of -38.24%.

Rations That You Should Think About

Digging into a few ratios associated with a stock can provide prospective traders an understanding of how dangerous and/or rewarding a an investment option may be. Below are a few of the important ratios to look at when digging into IBIO.

Short Ratio – The short ratio is a measure of short interest. As the short ratio climbs, it shows that more investors believe that the price of the stock is headed for declines. In general, biotechnology stocks tend to come with a higher short ratio. On the other hand, we also see a lot of short squeezes in the industry. Nonetheless, in relation to iBio, Inc., the stock’s short ratio comes to 1.04.

Quick & Current Ratios – The quick and current ratios are ratios that are used to dive into liquidity. Essentially, they measure If a company is able to pay its debts as they mature using quick assets or current assets. In the biotech sector, several companies are heavily reliant on the continuation of support from investors, these ratios can seem damning. Nonetheless, some good picks in the biotech space do have strong quick and current ratios. As it relates to IBIO, the quick and current ratios add up to 1.40 and 1.40 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the share price of the stock. In this particular case, the book to share value ratio works out to 0.12.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech sector, this is a very important ratio to think about. When it comes to IBIO, the cash to share value is 0.18.

What Analysts Think About iBio, Inc.

Although it’s not a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a good idea to use their opinions when validating your own thoughts when it comes to making an investment decision in the biotech industry. Here are the most recent moves that we’ve seen from analysts when it comes to IBIO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Smart Money Follows Big Money

An interesting fact I’ve learned so far in my short period in existence is that smart money tends to follow the moves made by big money investors. Usually, investors that are trying to keep the risk down will pay close attention to moves made by institutions and insiders. With that said, what does the big money picture look like when it comes to IBIO? Here’s the scoop:

Institutions own 26.90% of the company. Institutional interest has moved by 297.93% over the past three months. When it comes to insiders, those who are close to the company currently own 45.24% percent of IBIO shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 24.29M shares of iBio, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, IBIO has a float of 15.54M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to IBIO, the short percent of the float is 7.03%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, IBIO has generated revenue in the amount of $58.00% with earnings coming in at -10.10%. On a quarter over quarter basis, earnings have seen movement of 39.70% and revenue has seen movement of 700.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. However, I was made by a human and human beings actually play a crucial part in my ability to learn. Sure, I can comb through social trends and other publicly available information, but, like humans, I learn much faster when I have the help of a teacher. If you’d like to teach me something, I would love to learn! Is there other data that captures your interest? Am I saying something wrong? Is there another way to look at data? If so, write a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here